**Supplemental Table 2**

|  |  |  |
| --- | --- | --- |
| **NAT (5’-3’)** | **Target** | **% viability** |
| **Doxorubicin (positive control)** | **Non-specific** | **14 +- 3.1 (B16F10)** |
|  **GAGGACAGTG/gtgagtcagt** | **RBD****(exon 3/Intron 4)** | **19% +/- 1.2 (A375)****15.2 +/- 0.8 (132N1)** |
| **TGGTTCTTACCCAGCCGCCG** | **BCL-xL** | **14.9 +- 0.9 (B16F10)** |

**Supplemental Table 2.** Activity of ASO targeting RBD or BCL-xL in B16F10, A375 and 132N1 cells.